A Phase Ia/Ib Study of the Combination of the FGFR Inhibitor Pemigatinib and the EGFR Inhibitor Afatinib in Advanced Refractory Solid Tumors
This study is testing a combination of two targeted cancer medications, Afatinib and Pemigatinib, for people with advanced solid tumors. Researchers want to find the safest highest dose of these medicines and see how well they work against cancers with specific genetic changes.
You may be able to join if you are 18 or older, can still do your normal daily activities, and have an advanced cancer that has not responded to standard treatments. Your tumor must also have specific genetic changes called FGFR alterations, confirmed by a lab test.
Participants will take the study medications, Afatinib and Pemigatinib, while doctors closely monitor their health and side effects. The main goal is to find out the right dose of these drugs when taken together.
This study is currently recruiting participants and takes place in Boston, Massachusetts, in the United States.
- 1Tests a combination of two targeted cancer drugs together.
- 2Aims to find the safest and most effective dose.
- 3Requires specific genetic changes in your tumor to join.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.